BIO-Europe Spring EBD Group BIO Image Map
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe Spring® 2015 Press Releases

November 20, 2014Spotlight on Paris Business Facts The Paris region is Europe's No. 1 business region with 842,000 businesses, from high tech sectors to traditional industrial activities. Paris is an innovation hotspot and has eight competitive clusters enhancing innovation, and the most generous research tax credits in Europe. There were 4,800 patents filed in the Paris region in 2012. 500 international companies enjoy the...  more ►

partnering360® Blog

November 26, 2014 Objectives of translational medicine One of the hardest parts of translational medicine is melding the two objectives of the academic institution versus the Pharmaceutical company. In a recap of a session from BIO-Europe®, Insight looks at some of the differences between the two entities. Academic institutions looks at the scientific... more ►

November 25, 2014 A glimpse of exciting presenting companies at Biotech Showcase™ 2015 Biotech Showcase 2015 is coming up January 12–14, 2015 in San Francisco, and it’s already apparent that the list of presenting companies is full of innovative and inspiring companies. For example, Cortendo is a Swedish biotech with a pioneering approach in the field of  orphan drugs and... more ►

November 21, 2014 Become a BIO-Europe Spring® 2015 exhibitor and enhance your brand! BIO-Europe Spring will take place this March 9-11, 2015 in Paris, France.  This is a dynamic area to stand out and be noticed.  There will be over 2,100 leading life science executives and decision makers will congregate in the exhibit hall between partnering meetings. These are your customers: »... more ►

November 18, 2014 Part II: Do you have what it takes to win over investors? Tips from VCs on pitching your company taken from BIO-Europe® 2014 The following is Part II of some of the tips and takeaways on giving a “perfect pitch,”  taken from the “Perfect Pitch” workshop at BIO-Europe® 2014 in Frankfurt, Germany on November 3. Doug MacDougall, President of MacDougall Biomedical Communications, led the interactive workshop where... more ►

November 17, 2014 How do investors perceive value? Senior Industry leaders will share their perspectives at Biotech Showcase™ 2015 Biotech Showcase™ 2015 biotechnology investor and partnering conference will take place January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco – Union Square.  The event brings executive-level delegates representing top public and private investment firms with the goal... more ►

partnering360:Insight Latest headlines from partnering360:Insight

November 11, 2014 Bayer committed to Open Innovation and Collaborators The Head of Global Drug Discovery at Bayer HealthCare and a Member of the Executive Committee, Andreas Busch described the strategy underlying partnering efforts that he said have delivered a very significant value to patients as well as to shareholders. more ►

November 11, 2014 Merck Serono embraces partnering in all its forms Executive VP and Head of Global Research and Development at Merck Serono, Luciano Rossetti is also a Member of the Executive Committee who joined the company in late July this year. He offered to share with the audience a perspective from what he called a brief tenure. more ►

November 11, 2014 European biotech poised for acceleration David Loew is Senior VP for Commercial Operations in Europe at Sanofi. Rather than focusing on the company, Loew turned the spotlight on a wider concern for promoting a stronger environment for biotechs and start-ups in Europe. more ►

November 11, 2014 Transformational deals that shaped the industry in 2014 Led by moderator David Stubbs, the Managing Director for Inverness Advisors, the goal for the panel was to provide insights for transformational deals of the past year. The session was led off by a truly transformational deal that saw the USD 14.2 billion divestiture by Merck of its consumer healthcare business to Bayer HealthCare in May, 2014. The deal makes Bayer the second-biggest over-the-counter drug maker behind Johnson & Johnson. more ►

November 11, 2014 Covagen and vasopharm: Driving the right deal from the sell side A partner with the law firm Dentons, Peter Homberg teased out insights from the executives of two biotechs who are on the leading edge of negotiations with large pharma companies, providing first-hand accounts of their experiences. more ►

Arrow Up

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO Image Map